Phase II Efficacy Study of AZD6244 in Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine. This study will also assess how safe and well tolerated AZD6244 is.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
require treatment but have failed one or two previous chemotherapeutic regimens that must have included oxaliplatin and/or irinotecan
have World Health Organisation (WHO) performance status 0-2 and life expectancy > 12 weeks
previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine
any recent surgery, unhealed surgical incision or severe concomitant condition which makes it undesirable for the patient to participate in the study
nausea and vomiting, chronic gastrointestinal disease or significant bowel resection that would preclude adequate absorption